Laurine Lagache | Oncology | Innovative Research Award

Published on by Cell Biologist

 

Innovative Research Award

Laurine Lagache
PRISM – Inserm U1192, France

Laurine Lagache
Affiliation PRISM – Inserm U1192
Country France
Scopus ID 59161941000
Documents 6
Citations 12
h-index 3
Subject Area Oncology
Event World Cell Biologist Awards
ORCID 0009-0000-4442-6642

Laurine Lagache is a researcher affiliated with PRISM – Inserm U1192 in France, with a research profile situated within the field of oncology. Her documented scholarly record comprises 6 documents, 12 citations, and an h-index of 3 according to the supplied Scopus profile information. [1] Her research context is relevant to contemporary cell biology and cancer research, disciplines in which cellular mechanisms, molecular interactions, disease progression, and therapeutic responses are closely interconnected. [2]

Abstract

The Innovative Research Award profile for Laurine Lagache presents a concise academic overview of a researcher working in oncology at PRISM – Inserm U1192, France. The profile is based on the supplied researcher identification and bibliometric information, including six indexed documents, twelve citations, and an h-index of three. [1] The research domain is positioned within the broader scientific landscape of oncology and cell biology, where investigation of cellular and molecular mechanisms contributes to understanding disease biology and developing improved approaches to diagnosis, prognosis, and treatment. [2]

Keywords

Laurine Lagache; Innovative Research Award; oncology; cell biology; cancer research; PRISM – Inserm U1192; biomedical research; molecular oncology; research impact; scientific innovation.

Introduction

Oncology is a multidisciplinary research field encompassing the biological mechanisms responsible for cancer development, progression, dissemination, and response to treatment. Modern cancer research increasingly integrates cellular biology, molecular biology, genetics, immunology, bioinformatics, and translational science to characterize disease processes at multiple levels. [2]

Research Profile

The supplied bibliometric profile identifies Laurine Lagache under Scopus Author ID 59161941000. The reported record contains 6 documents, 12 citations, and an h-index of 3. [1] These indicators provide quantitative information about indexed scholarly output and citation activity, but they should be interpreted in conjunction with publication quality, authorship contribution, research relevance, and the scientific context of the work.

Research Contributions

The available information establishes oncology as the principal subject area associated with the researcher profile. On this basis, the relevant contribution can be considered within the wider scientific objective of improving knowledge of cancer biology and its cellular and molecular foundations. However, the supplied data do not provide sufficient evidence to attribute a particular discovery, technique, therapeutic intervention, or clinical finding to Laurine LAGACHE. [4]

Publications

The supplied Scopus profile records 6 documents associated with the researcher identifier. [1] The available input does not provide individual publication titles, journals, publication years, author positions, or article-level DOI identifiers. Consequently, no specific publication is attributed to Laurine LAGACHE in this profile beyond the supplied bibliometric record.[3] [5]

Research Impact

The reported citation count of 12 and h-index of 3 indicate measurable scholarly citation activity within the supplied Scopus record. [1] Citation indicators can be useful for understanding the visibility of research outputs, although they do not independently establish the quality, originality, societal value, or practical significance of research. [3]

Award Suitability

Based on the supplied information, Laurine Lagache research profile is aligned with the scientific scope of an Innovative Research Award through its stated focus on oncology and its documented scholarly activity. The profile provides identifiable affiliation, research area, indexed documents, citations, h-index, and a persistent ORCID identifier, which together provide a basis for academic profile verification. [1] [3]

Conclusion

Laurine Lagache is presented as an oncology researcher affiliated with PRISM – Inserm U1192 in France. The supplied profile records 6 Scopus-indexed documents, 12 citations, and an h-index of 3, together with Scopus Author ID 59161941000 and ORCID 0009-0000-4442-6642. [1] [3]

References

  1. Elsevier. (n.d.). Scopus author details: Laurine LAGACHE, Author ID 59161941000. Scopus.
    https://www.scopus.com/pages/authors/59161941000
  2. L Lagache,D Simon, GS Horkovics-Kováts, et al. (2025). Subcellular-Resolution Molecular Pathology by Laser Ablation–Rapid Evaporative Ionization Mass Spectrometry.
    https://pubs.acs.org/ancham/article-abstract/97/32/17433/3622698
  3. L Lagache, J Salzet, I Fournier, M Salzet. (2026). Beyond Darwin: reactive heredity, burst-drift dynamics and eco‑evolutionary control of cancer.
    https://link.springer.com/article/10.1186/s12943-026-02683-w
  4. A Goossen, L Lagache, et al. (2026). A Universal Modular High-Plex MALDI Mass Spectrometry Imaging Platform.
    https://www.researchsquare.com/article/rs-9525563/v1
  5. L Lagache, M Salzet. (2026). Metastasis as a breakdown of the multicellular social contract.
    https://link.springer.com/article/10.1007/s10555-026-10352-z

Pengyu Jing | Lung Cancer Progression | Research Excellence Award

Published on by Cell Biologist

Mr. Pengyu Jing | Lung Cancer Progression | Research Excellence Award

The Second Affiliated Hospital of Air Force Medical University | China

A thoracic surgery specialist with extensive experience in minimally invasive treatment of lung cancer, mediastinal tumors, and pulmonary diseases, focusing on multidisciplinary clinical approaches including surgery, biopsy, and ablation. Research interests center on tumor microenvironment, epigenetics, antitumor drug development, and pulmonary fibrosis modeling. Has led multiple national and provincial research projects and contributed to international clinical trials. Authored over 20 SCI-indexed publications with significant impact in oncology and cell biology, particularly on PRMT5-related mechanisms in lung cancer progression and therapy resistance. Actively involved in academic editorial work, peer review, and professional scientific committees, contributing to advancements in thoracic oncology research and clinical practice.

Citation Metrics (Scopus)

600
400
200
100
50
20
0

Citations
581

Documents
27

h-index
12

Citations

Documents

h-index

Featured Publications

Prof. JY Guo | Cancer Cell Biology | Women Researcher Award

Published on by Cell Biologist

Prof. JY Guo | Cancer Cell Biology | Women Researcher Award

Youjiang Medical University for Nationalities | China

A cross-disciplinary researcher specializing in pharmaceutical and analytical chemistry, with expertise in integrating traditional herbal medicine and modern nanotechnology. Research focuses on isolating bioactive compounds, developing hydrogel-based medical materials, and designing nanoparticle and vaccine systems for cancer therapy. Has led multiple national and regional research projects, published extensively in peer-reviewed journals, and contributed to advancements in biomaterials and drug development. Work also includes metabolomics and mass spectrometry imaging. Actively involved in academic collaborations, editorial responsibilities, and professional organizations, supporting innovation in pharmaceutical sciences and translational medicine.

 

Citation Metrics (Scopus)

800
600
400
200
100
50
0

Citations
718

Documents
16

h-index
10

Citations

Documents

h-index

Featured Publications

Mr. Rahul Das Gupta | Cancer Cell Biology | Editorial Board Member

Published on by Cell Biologist

Mr. Rahul Das Gupta | Cancer Cell Biology | Editorial Board Member

Maulana Abul Kalam Azad University of Technology | India

Rahul Das Gupta is a biotechnology researcher with expertise in cancer biology, nanomedicine, and computational drug discovery. His work focuses on exosome-based liquid biopsy for early brain cancer detection and in-silico screening of plant-derived anticancer compounds targeting oncogenic pathways. He has synthesized bio-metallic nanoparticles using medicinal plant extracts and evaluated their antimicrobial and cytotoxic potential through experimental and computational approaches, including EGFR and VEGFR interaction studies. Skilled in molecular biology, cell culture, bioinformatics, and advanced characterization techniques, he integrates laboratory research with computational analysis. His publication in Biochemical and Biophysical Research Communications highlights his contributions to translational cancer research.

Citation Metrics (Google Scholar)

2
1.5
1
0.5
0

Citations
2

h-index
1

i10-index
0

Citations

h-index

i10-index

Featured Publications

Yida Huang | Cancer Metabolomics | Research Excellence Award

Published on by Cell Biologist

Dr. Yida Huang | Cancer Metabolomics | Research Excellence Award

Shanghai Jiao Tong University | China

Dr. Yida Huang is an accomplished postdoctoral researcher recognized through highly competitive national talent programs, including the Postdoctoral Innovative Talent Support Program and NSFC Doctor Program. Their research centers on advanced mass spectrometry–based molecular profiling technologies for precision diagnosis and prognosis of diseases, particularly cancer. To date, they have published 28 peer-reviewed articles in leading international journals such as Cell Reports Medicine, Gut, PNAS, and Materials Today Bio, including two ESI Highly Cited Papers. With 588 citations and an h-index of 12, their work demonstrates strong scientific influence. They have led multiple nationally and municipally funded projects and contributed to translational innovation through five invention patents. A major achievement includes developing a nano-solid-phase mass spectrometry platform enabling high-throughput metabolic profiling from diverse biological samples, supporting large-scale cancer biomarker discovery and prognostic modeling with clinical accuracy comparable to conventional staging systems.

Citation Metrics (Google Scholar)

600
400
200
100
50
0

Citations
596

Documents
28

h-index
13

Citations

Documents

h-index

i10-index: 16

Featured Publications

Sakarie Mustafe Hidig | Cancer Cell Biology | Research Excellence Award

Published on by Cell Biologist

Dr. Sakarie Mustafe Hidig | Cancer Cell Biology | Research Excellence Award

Zhejiang University School of Medicine | United Kingdom

Dr. Sakarie Mustafe Hidig is a General Surgeon, Clinical Researcher, and Editor-in-Chief affiliated with Zhejiang University School of Medicine and the Research Center at Hargeisa Group Hospital. He serves as the UK Country Coordinator for the International Institute of Knowledge Management (TIIKM) and is an active member of the China Medical Association, Somali Medical Association, and the Scholars Academic and Scientific Society. Dr. Hidig has earned multiple international honors, including the SHEN Best Researcher Awards, GCDMSE-2024, and ISSN Research Awards. With over 70 published papers, 280+ SCI editorial handling experiences, and 14 research projects, his work spans general, gastrointestinal, trauma, emergency, hepatobiliary, and pancreatic surgery. He also contributes as an editor for major journals such as PLOS One Medicine, Annals of Medicine and Surgery, Obesity Surgery, and JMIR Public Health and Surveillance. His research interests include surgical oncology, hepatology, pancreatic cancer, and public health.

Citation Metrics (Scopus)

40

30

20

10

0

Citations
12

Documents
7

h-index
2

Citations
Documents
h-index



View Scopus Profile

Featured Publication

Hongjin Liu | Cancer Cell Biology | Research Excellence Award

Published on by Cell Biologist

Dr. Hongjin Liu | Cancer Cell Biology | Research Excellence Award

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College | China

Hongjin Liu is a medical oncologist whose research centers on cancer biology, therapeutic resistance, and tumorigenesis. His work spans molecular oncology, hepatocellular carcinoma, and mechanisms of somatic mutagenesis across human tissues. He has contributed to high-impact studies published in Nature and Signal Transduction and Targeted Therapy, including investigations uncovering the landscape of somatic mutations in normal tissues and the critical role of VAV2 in DNA repair and radiotherapy resistance. His research also explores noncoding RNA–mediated regulatory networks in liver cancer, notably identifying the oncogenic function of ELF3-AS1 through its modulation of the miR-98-5p/CPSF4 axis. Collectively, his publications provide important insights into genomic instability, tumor microenvironment dynamics, and potential molecular targets for improving therapeutic outcomes. His translational research aims to bridge molecular mechanisms with clinical oncology to support precision cancer treatment and advance strategies for overcoming therapy resistance.

Profile: Orcid

Featured Publications: 

1. Ge, P., Niu, S., Fang, M., Xu, Q., Zhang, W., Xu, J., Yang, F., Wang, Y., Shi, T., & Liu, H. (2025). ELF3-AS1 promotes the carcinogenesis of hepatocellular carcinoma cells by inhibiting miR-98-5p/CPSF4 axis. Nucleosides, Nucleotides & Nucleic Acids.

2. Zhang, W., Liu, Z., Liu, H., Huang, Z., Huang, X., Xu, L., Che, X., & Zhan, Z. (2025). The impact of immune checkpoint inhibitors on prognosis in unresectable hepatocellular carcinoma treated with TACE and lenvatinib: A meta-analysis. Frontiers in Immunology.

3. Liu, W., Miao, C., Zhang, S., Liu, Y., Niu, X., Xi, Y., Guo, W., Chu, J., Lin, A., Liu, H., Yang, X., Chen, X., Zhong, C., Ma, Y., Wang, Y., Zhu, S., Liu, S., Tan, W., Lin, D., & Wu, C. (2021). VAV2 is required for DNA repair and implicated in cancer radiotherapy resistance. Signal Transduction and Targeted Therapy, 6(9), 2906–2919.

4. Li, R., Di, L., Li, J., Fan, W., Liu, Y., Guo, W., Liu, W., Liu, L., Li, Q., Chen, L., Chen, Y., Miao, C., Liu, H., Wang, Y., Ma, Y., Xu, D., Lin, D., Huang, Y., Wang, J., Bai, F., & Wu, C. (2021). A body map of somatic mutagenesis in morphologically normal human tissues. Nature, 597(7876), 398–403.

5. Chen, Y., Zeng, Q., Liu, X., Fu, J., Zeng, Z., Zhao, Z., Liu, Z., Bai, W., Dong, Z., & Liu, H. (2018). LINE-1 ORF-1p enhances the transcription factor activity of pregnenolone X receptor and promotes sorafenib resistance in hepatocellular carcinoma cells. Cancer Management and Research, 10, 6345–6358.

Varsha Rathore | Cancer Biology | Best Researcher Award

Published on by Cell Biologist

Dr. Varsha Rathore | Cancer Biology | Best Researcher Award

Department of Pharmacology, College of Medicine, National Taiwan University, Taipei 100233 | Taiwan

Dr. Varsha Rathore’s research focuses on elucidating the molecular mechanisms underlying cancer cell migration, invasion, and survival, with a particular emphasis on the role of CASK (Calcium/Calmodulin-dependent Serine Protein Kinase) in prostate cancer progression. Her doctoral work explores how CASK promotes tumor cell motility and invasiveness independent of TGF-β signaling, contributing to a deeper understanding of tumor metastasis. Additionally, she investigates the involvement of NLRX1 in regulating proliferation, invasion, and survival pathways in prostate cancer cells, offering insights into novel therapeutic targets for cancer treatment. Her expertise spans cell culture, molecular biology, and biochemical assays, including protein expression, purification, ubiquitination, kinase, and PARylation assays, as well as metabolic analysis using Seahorse technology. She has presented her findings at international conferences, including the 19th World Congress of Basic and Clinical Pharmacology and the 38th Joint Academic Conference on Biomedicine. Through her research, Dr. Rathore contributes significantly to the field of molecular oncology and pharmacology, advancing knowledge on how signaling proteins orchestrate cancer progression and identifying potential molecular targets for therapeutic intervention.

Profile: Orcid

Featured Publications:

Rathore, V., Cheng, C.-Y., Lin, C.-Y., Chang, C.-R., & Lin, W.-W. (2025). CASK promotes prostate cancer progression via kinase-dependent activation of AKT. International Journal of Biological Macromolecules, 311(Pt 2), 143965.

Rathore, V., & Lin, W.-W. (2025). Decoding SIGLEC12 in bladder cancer: In silico profiling of expression, tumor–immune interactions, and prognostic impact. Medicina, 61(11), 1894.

Mishra, M., Rathore, V., Sahu, S., & Sahoo, H. (2019). The contribution of nanostructures towards the wing patterning of yellow Catopsilia pomona: How it differs from the lime. Microscopy, 68(4), 289–300.

Shaoqing Ai | Cancer | Best Researcher Award

Published on by Cell Biologist

Mr. Shaoqing Ai | Cancer | Best Researcher Award

Xi’an Daxing Hospital | China

Dr. Shaoqing Ai’s research focuses on the clinical application and translational potential of integrated traditional Chinese and Western medicine in oncology, particularly in the management of gastrointestinal tumors, lung cancer, and gynecological malignancies. His work emphasizes optimizing multidisciplinary treatment strategies and improving patient outcomes through precision diagnosis and therapy. As an active contributor to the fields of tumor metastasis and geriatric oncology, he has participated in a research project exploring the molecular mechanisms and clinical management of tumor progression and treatment-related complications. His published studies, including one SCI-indexed paper and two Chinese core journal articles, highlight the therapeutic efficacy of combined treatment approaches in reducing radiotherapy- and chemotherapy-induced hematologic toxicities such as leukopenia and thrombocytopenia. Dr. Ai’s research also aims to refine clinical protocols for mitigating adverse effects while enhancing the overall quality of life for cancer patients. Through his involvement in professional oncology committees and collaborative studies, he continues to advance the integration of evidence-based Chinese medicine with modern oncological practices, contributing to the growing body of knowledge supporting individualized and holistic cancer care.

Profile: Orcid

Featured Publications:

Ai, S., Jun, G., Jia, W., & Jie, L. (2025, October 16). Correlation analysis between frequency of gastrointestinal bleeding episodes and abnormal coagulation indexes in digestive system tumors. Scientific Reports. https://doi.org/10.1038/s41598-025-19012-8

 

 

Waldemar Debinski | Cancer Cell Biology | Best Researcher Award

Published on by Cell Biologist

Prof. Dr. Waldemar Debinski | Cancer Cell Biology | Best Researcher Award

Wake Forest School of Medicine | United States

Dr. Waldemar Debinski, M.D., Ph.D., is a distinguished neuroscientist and cancer researcher recognized for his pioneering work in brain tumor biology and targeted molecular therapies. His research focuses on understanding the molecular mechanisms that drive the development and progression of malignant brain tumors, with a particular emphasis on gliomas. Dr. Debinski has significantly contributed to the development of novel targeted therapeutics, including receptor-directed cytotoxins and biologics designed to selectively eliminate tumor cells while sparing healthy tissues. His investigations bridge molecular oncology, translational science, and clinical application, aiming to improve therapeutic outcomes for patients with brain cancers. Throughout his career, he has integrated insights from physiology, molecular biology, and pharmacology to develop translational approaches that move from laboratory discovery to clinical implementation. His extensive research has advanced the understanding of tumor-specific receptors and intracellular signaling pathways, contributing to innovative strategies in cancer immunotherapy and precision medicine. Dr. Debinski’s work exemplifies the integration of basic and clinical research toward the development of next-generation treatments for central nervous system malignancies, positioning him as a leading figure in neuro-oncology and translational cancer research.

Profile: Scopus

Featured Publications:

Wocial, B., Januszewicz, W., Siedlecki, J., Feltynowski, T., & Debinski, W. (1982). Alterations in plasma dopamine-β-hydroxylase and catecholamine concentrations during surgical removal of pheochromocytoma. Endocrinologie, 79, 131–139.

Debinski, W., & Wocial, B. (1982). Various aspects of sodium metabolism in hypertension [in Polish]. Polski Tygodnik Lekarski, 37, 1339–1342.

Ignatowska-Świtalska, H., Debinski, W., & Chojnowski, K. (1983). The role of certain hormonal factors in arterial hypertension [in Polish]. Materia Medica Polona, 15, 74–86.

Wasawska, T., Feltynowski, T., Majewska, Z., Januszewicz, W., Sobolewska-Karwowska, A., Wocial, B., & Debinski, W. (1984). Pheochromocytoma: Description of two cases with an unusual clinical picture [in Polish]. Polski Tygodnik Lekarski, 39, 261–263.

Czarkowski, M., & Debinski, W. (1984). Sodium and primary arterial hypertension [in Polish] (Review). Kardiologia Polska, 27, 967–976.

Wocial, B., Debinski, W., Jablonska-Skwicinska, E., Feltynowski, T., Chodakowska, J., Kozakowska, E., & Januszewicz, W. (1984). Sodium content of erythrocytes in patients with arterial hypertension [in Polish]. Polski Archiwum Medycyny Wewnetrznej, 72, 167–174.

Garcia, R., Debinski, W., Gutkowska, J., Kuchel, O., Thibault, G., Genest, J., & Cantin, M. (1985). Gluco- and mineralocorticoids may regulate the natriuretic effect and the synthesis and release of atrial natriuretic factor by the rat atria in vivo. Biochemical and Biophysical Research Communications, 131, 806–814.

Debinski, W., Kuchel, O., Garcia, R., Buu, N. T., Racz, K., Cantin, M., & Genest, J. (1986). Atrial natriuretic factor inhibits sympathetic activity in one-kidney, one-clip hypertension in the rat. Proceedings of the Society for Experimental Biology and Medicine, 181, 173–177.

Debinski, W., Kuchel, O., Buu, N. T., Garcia, R., Cantin, M., & Genest, J. (1986). Involvement of the adrenal glands in the action of the atrial natriuretic factor. Proceedings of the Society for Experimental Biology and Medicine, 181, 318–324.

Debinski, W., Gutkowska, J., Kuchel, O., Racz, K., Buu, N. T., Cantin, M., & Genest, J. (1986). ANF-like peptide(s) in the peripheral autonomic nervous system. Biochemical and Biophysical Research Communications, 134, 279–284.